Cambridge Bioscience is a well established, leading European distributor of life science products bringing new and exciting technologies to researchers. Working with over forty specialist suppliers around the world, we offer an innovative, extensive and diverse range of over 450,000 products, services and instruments supporting research in the areas of drug discovery, regenerative medicine, cell culture and much more.
The products and services Cambridge Bioscience offers includes:
· Ion Channel, GPCR & Kinase Profiling Services
· Primary screening & Secondary Drug Profiling Services
· Cardiac Safety Assessment
· Ion Channel & GPCR Cell Lines
· Human Tissues, TMAs & Biofluids
· Primary Cells & Cell Culture Technologies
To find out more, please meet us at the event or contact us using the details below
Tel: +44 (0)1223 316 855
Fax: +44 (0)1954 781 323
Dr Vashu PamnaniSenior Business Manager
Established in 1982, Chiltern is a leading global clinical CRO offering specialized services in all phases of oncology, hematology and a range of other therapeutic areas, together with global sourcing and functional service provider (FSP) solutions. Chiltern’s 2,100 people work in more than 40 countries and offer expertise, engagement and tailored, responsive solutions to meet the demands of biotech and pharmaceutical partners of all sizes.
Ms Juliette AlmondGlobal Manager, Client Services - oncology
Ms Andrea Cotton-BerryGlobal Director, Client Services - Oncology
Mr Michael BakerVP, Oncology
Mr Lewis CameronGlobal Head, Oncology
Critical Pharmaceuticals is a privately funded clinical stage biotechnology company focused on developing improved versions of marketed biologic drugs using it’s patented drug delivery platform technologies.
The company’s lead products are an intranasal human growth hormone product, targeted at a $3.1bn market, and CP046 intranasal teriparatide product for the treatment of osteoporosis, a $1.2bn market. The development pathway for both programs is clear and low risk as it involves drugs with well established efficacy and toxicity, and previous exposure to man in a successful Phase I clinical trials.
Critical Pharmaceuticals patented CriticalMix™ and CriticalSorb™ technology platforms are applicable to the large and fast growing market of biological drugs. The technology has been validated in collaboration with other biopharmaceutical companies with two partner programs poised to enter clinical development.
The products and platform technology has extensive IP protection, including granted US patents.
Dr Gareth KingCEO
Datatrial is a clinical technology organisation with supporting biometrics services. Our innovative nowEDC™ solution provides data capture, verification and validation, query management, data extract, randomization and real-time reporting in one integrated system. nowEDC is easy-to-use and is highly configurable, making it a natural fit for complex workflows and trial designs.
Dr Emma BanksCEO
Miss Amy WrightBusiness Development Associate
Glythera Limited is a biotechnology company specializing in the development of platform technologies for next generation biotherapeutics. We have 2 core programmes:
- PermaLink™ - a novel, stable, highly cysteine-specific conjugation platform for antibody drug conjugates (ADCs)
PermaLink™ is associated with enhanced anti-tumour activity in vivo vs maleimide in comparative ADC models. It is suitable for cleavable and non-cleavable systems
- PermaCarb™ - a novel sialylation correction platform which can (i) improve bioavailability & enhance product performance and (ii) remove the issue of sialic acid contamination. It is particularly appropriate for the development of biobetters and biosimilars
PermaCarb™ has been validated vs several biotherapeutics, including FSH and etanercept
Based in the NE of England, Glythera has dedicated bioprocessing and chemistry laboratories enabling us to conduct in-house evaluations for our partners to progress applications of PermaLink™ and PermaCarb™ technologies.
We are seeking license collaborations for PermaLink™ and out-license partners for PermaCarb™
Dr Ian EvettsCommercial Director
Dr Dave SimpsonCEO
KWS BioTest Ltd.
KWS BioTest is an established contract research organization providing a wide range of drug discovery services spanning preclinical development from early cell biology, through efficacy models to clinical sample analysis.
KWS BioTest provides clients with a powerful combination of world-leading scientific expertise coupled with the latest methods and technologies to ensure the highest levels of quality and service at all times. We specialise in the areas of immunology, inflammation and infection and work closely with our clients in the testing of their novel small molecules, biologics and ADCs as treatments for human disease, including specific experience across global vaccine development initiatives. We can generate data to support all stages of compound and molecule development to maximise the chance of successful progression to each important project milestone.
Our dedicated solutions for our clients often feature bespoke study designs, allowing them to benefit from our extensive experience across both therapeutic areas and molecule classes. Our team of expert scientists can provide support for both individual studies and as part of larger projects as a virtual extension of our clients’ laboratory capabilities. We can assist in the interpretation of complex programs of work in target validation, lead optimisation, candidate selection, discovery support and clinical sample analysis, increasing the chance of molecules succeeding and helping bring them to the clinic faster.
Mr Simon JohnsHead of Business Development
The Randox Group is a global force in the clinical diagnostics, life sciences, pharma services and forensic toxicology industries. Through innovation and focus, Randox has now grown to incorporate 8 divisions, two of which are joining you at Bio-Europe; Randox Lifesciences and Randox Pharma Services.
Randox Life Sciences is a recognised primary manufacturer of high-quality, cost effective human recombinant proteins and antibodies targeting a broad range of small and large molecules such as drugs of abuse, steroids, hormones and protein biomarkers. At Bio-Europe we are presenting our newest product offering, camelid Single Domain Antibodies, which due to their very small size, high stability and low immunogenicty can be used in many therapeutic and diagnostic applications including molecular imaging, as receptor/enzyme antagonists, as intrabodies and in the generation of bispecific/multivalent scaffolds and constructs. We are seeking partners and clients interested in engaging with Randox as their chosen supplier of diagnostic, therapeutic and research proteins and antibodies to facilitate and fast track their commercial requirements.
Randox Pharma Services supplies the world’s leading pharmaceutical and biotech companies with an extensive range of clinical diagnostic solutions and biomarker development. This includes multiplexed protein and nucleic acid arrays, clinical chemistry assays, quality control materials and the development of companion diagnostics. As a primary IVD manufacturer with a full service including; assay development, instrumentation, quality assurance and regulatory affairs we can take a candidate biomarker from assay development to companion diagnostic PMA submission and global distribution in a timely and cost effective manner.
source: Partnering360 (29/10/2014)